ZA9510909B - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
ZA9510909B
ZA9510909B ZA9510909A ZA9510909A ZA9510909B ZA 9510909 B ZA9510909 B ZA 9510909B ZA 9510909 A ZA9510909 A ZA 9510909A ZA 9510909 A ZA9510909 A ZA 9510909A ZA 9510909 B ZA9510909 B ZA 9510909B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
ZA9510909A
Other languages
English (en)
Inventor
Philip Anthony Ashworth
Sukhjit Hunjan
Ian Andrew Pretswell
Hamish Ryder
Stephen James Brocchini
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Priority to TW084113836A priority Critical patent/TW358094B/zh
Publication of ZA9510909B publication Critical patent/ZA9510909B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9510909A 1994-12-23 1995-12-21 Pharmaceutical compounds ZA9510909B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW084113836A TW358094B (en) 1994-12-23 1995-12-23 Piperazinedione derivatives, their preparation and their use as moduators of multi-drug resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9426224.3A GB9426224D0 (en) 1994-12-23 1994-12-23 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ZA9510909B true ZA9510909B (en) 1996-08-30

Family

ID=10766589

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9510909A ZA9510909B (en) 1994-12-23 1995-12-21 Pharmaceutical compounds

Country Status (19)

Country Link
EP (1) EP0799222A1 (cs)
JP (1) JPH10511384A (cs)
CN (1) CN1175253A (cs)
AU (1) AU698828B2 (cs)
BG (1) BG101602A (cs)
BR (1) BR9510410A (cs)
CA (1) CA2207500A1 (cs)
CZ (1) CZ190097A3 (cs)
FI (1) FI972660A7 (cs)
GB (1) GB9426224D0 (cs)
HU (1) HUT77943A (cs)
IL (1) IL116525A0 (cs)
NO (1) NO972937L (cs)
NZ (1) NZ297847A (cs)
PL (1) PL320916A1 (cs)
SK (1) SK83697A3 (cs)
TW (1) TW358094B (cs)
WO (1) WO1996020190A1 (cs)
ZA (1) ZA9510909B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
CN100354265C (zh) * 1996-10-18 2007-12-12 埃克森诺瓦有限公司 邻氨基苯甲酸衍生物及其制备方法和作为多种抗性调节剂的用途
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
SK4782001A3 (en) 1998-10-08 2001-11-06 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
MXPA02006826A (es) * 2000-01-18 2004-04-05 Nereus Phamraceuticals Inc Un inhibidor de division celular y un metodo de produccion del mismo.
US7220414B2 (en) 2000-09-06 2007-05-22 A.P. Pharma, Inc. Degradable polyacetal polymers
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ATE374767T1 (de) 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN103396372B (zh) * 2013-08-09 2015-05-20 中国科学院南海海洋研究所 一类2,5-二酮哌嗪衍生物及其制备方法和在制备抗海洋污损生物防除剂中的应用
CA2978679A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
CA2978567A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation using plinabulin
KR102680823B1 (ko) 2015-07-13 2024-07-03 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103479T3 (es) * 1992-07-10 1997-09-16 Glaxo Lab Sa Derivados de anilida.
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
PL320916A1 (en) 1997-11-10
SK83697A3 (en) 1998-05-06
AU698828B2 (en) 1998-11-05
FI972660L (fi) 1997-08-22
FI972660A7 (fi) 1997-08-22
CN1175253A (zh) 1998-03-04
FI972660A0 (fi) 1997-06-19
BG101602A (en) 1998-02-27
NZ297847A (en) 1999-04-29
CZ190097A3 (cs) 1998-01-14
WO1996020190A1 (en) 1996-07-04
AU4310096A (en) 1996-07-19
HUT77943A (hu) 1998-12-28
GB9426224D0 (en) 1995-02-22
NO972937D0 (no) 1997-06-23
BR9510410A (pt) 1999-09-08
IL116525A0 (en) 1996-03-31
TW358094B (en) 1999-05-11
JPH10511384A (ja) 1998-11-04
NO972937L (no) 1997-06-23
EP0799222A1 (en) 1997-10-08
CA2207500A1 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
GB9502874D0 (en) Pharmaceutical compounds
ZA959921B (en) Pharmaceutical compounds
GB9602080D0 (en) Pharmaceutical compounds
ZA954226B (en) Pharmaceutical compounds
GB2286394B (en) Pharmaceutical compounds
GB9426224D0 (en) Pharmaceutical compounds
GB9502861D0 (en) Pharmaceutical compounds
GB9609976D0 (en) Pharmaceutical compounds
ZA957607B (en) Pharmaceutical compounds
GB9417102D0 (en) Pharmaceutical compounds
ZA9510903B (en) Pharmaceutical compounds
GB9426080D0 (en) Pharmaceutical compounds
GB9402805D0 (en) Pharmaceutical compounds
ZA956419B (en) Pharmaceutical compound
ZA944689B (en) Pharmaceutical compounds
GB9417526D0 (en) Pharmaceutical compounds
GB9402889D0 (en) Pharmaceutical compounds
SG32533A1 (en) Pharmaceutical compounds
SG32534A1 (en) Pharmaceutical compounds
GB9402806D0 (en) Pharmaceutical compounds
GB9425040D0 (en) Pharmaceutical compounds
ZA941781B (en) Pharmaceutical compounds
GB9426092D0 (en) Pharmaceutical compounds
GB9417322D0 (en) Pharmaceutical compounds
GB9417514D0 (en) Pharmaceutical compounds